Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

56.97USD
3:25pm EDT
Change (% chg)

$-0.91 (-1.57%)
Prev Close
$57.88
Open
$57.78
Day's High
$58.75
Day's Low
$56.02
Volume
32,637
Avg. Vol
51,473
52-wk High
$66.38
52-wk Low
$13.01

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $880.63
Shares Outstanding(Mil.): 15.21
Dividend: --
Yield (%): --

Financials

  URGN.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -- -- --
ROI: -- -0.75 13.17
ROE: -- -2.86 14.98

BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74

* UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

Jan 18 2018

BRIEF-Urogen Announces Proposed Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

Jan 16 2018

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

Nov 14 2017

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​ Source: (http://bit.ly/2hdmj4k) Further company coverage:

Nov 08 2017

Earnings vs. Estimates